01—Abstract
Summary
Summary of the 10-K filed February 6, 2009. Cited figures are marked; the original filing is the authoritative source.
Biogen Idec Inc. (BIIB) reported strong financial performance for the year ended December 31, 2008, with total revenues reaching $4.1 billiona.
The company's primary revenue drivers, AVONEX (for multiple sclerosis) and RITUXAN (for lymphoma and rheumatoid arthritis), continued to show robust sales growth, contributing approximately 81% of total revenues. TYSABRI, a newer product for multiple sclerosis and Crohn's disease, demonstrated significant revenue growth, indicating increasing market acceptance despite ongoing safety monitoring. The company significantly increased its investment in research and development, spending over $1 billionb to advance its pipeline, with 22 products in Phase 2 trials or beyond.
This strategic investment highlights Biogen Idec's commitment to future growth through innovation in neurology, oncology, and immunology. Despite the company's strong financial position and product portfolio, it faces increasing competition and the potential impact of biosimilars on its key products. The report also details ongoing collaborations and potential future product development, providing a comprehensive view of the company's operational and strategic landscape.
02—Key points
Key Highlights
- Total revenues reached $4.1 billion, driven by strong performance in AVONEX and RITUXAN.
- TYSABRI demonstrated significant revenue growth, indicating increasing market acceptance.
- Research and development expenses increased by 16.5% to $1.07 billion, with 22 pipeline products in Phase 2 or beyond.
- The company continues to face competition in the MS market from existing and emerging therapies.
- Royalty revenues from RITUXAN outside the U.S. are expected to decrease significantly starting in the latter half of 2009 due to patent expirations.
- Biogen Idec completed a significant tender offer in July 2007, repurchasing over 56 million shares.
- The company is actively managing its intellectual property portfolio, with key patents for RITUXAN expiring between 2015 and 2018.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2008, Biogen Inc. kept $0.19.
- Revenue$4.10B100.0%
- Cost of revenue−$402.0M9.8%
- Gross profit$3.70B90.2%
- Operating costs−$2.48B60.6%
- Operating income$1.21B29.6%
- Interest, other & tax−$430.4M10.5%
- Net income$783.2M19.1%
Where FY2008 revenue went
$4.10B- R&D: $1.07B, 26% of revenue
- SG&A: $925.3M, 23% of revenue
- Net income: $783.2M, 19% of revenue
- Cost of revenue: $402.0M, 9.8% of revenue
- Other operating costs: $484.5M, 12% of revenue
- Interest, other & tax: $430.4M, 11% of revenue
Kept 19% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2008filed February 6, 2009Financial Statements
FY2008 against FY2007
| Line item | FY2008FY2007 | Change |
|---|---|---|
| Revenue | $4.10B$3.17B | +29.2% |
| Cost of Revenue | $401.99M$335.19M | +19.9% |
| Gross Profit | $3.70B$2.84B | +30.3% |
| R&D Expenses | $1.07B$925.16M | +15.9% |
| SG&A Expenses | $925.30M$776.10M | +19.2% |
| Operating Expenses | $2.88B$2.39B | +20.6% |
| Operating Income | $1.21B$779.77M | +55.6% |
| Interest Expense | $52.00M— | — |
| Net Income | $783.17M$638.17M | +22.7% |
| EPS (Basic) | $2.67$2.02 | +32.2% |
| EPS (Diluted) | $2.65$1.99 | +33.2% |
| Shares Outstanding (Basic) | 292.33M315.84M | −7.4% |
| Shares Outstanding (Diluted) | 294.98M320.17M | −7.9% |
05—Questions
Frequently Asked Questions
What were Biogen Idec's key revenue-generating products in 2008?
Biogen Idec's primary revenue drivers were AVONEX, used to treat multiple sclerosis, and RITUXAN, used for certain B-cell non-Hodgkin's lymphoma and rheumatoid arthritis. These two products accounted for approximately 81% of the company's total revenues in 2008.
How is TYSABRI performing in the market?
TYSABRI showed significant revenue growth in 2008, reaching $588.6 million. This growth indicates increasing market acceptance for treating relapsing MS and Crohn's disease. However, the company continues to monitor the known side effect of PML (progressive multifocal leukoencephalopathy) and is developing protocols to mitigate risks.
What is Biogen Idec's strategy for future growth?
Biogen Idec's long-term growth strategy relies on the successful development and commercialization of its research and development pipeline. The company significantly increased R&D spending in 2008 to over $1 billion, focusing on novel therapeutics in neurology, oncology, and immunology. This includes actively managing 22 pipeline products in Phase 2 trials or further along.
What are the key risks facing Biogen Idec?
Key risks include substantial dependence on AVONEX and RITUXAN revenues, the market acceptance and safety profile of TYSABRI, intense competition from other biotechnology and pharmaceutical companies, potential emergence of biosimilars, and regulatory and reimbursement challenges within the healthcare industry. Additionally, the company faces risks related to patent expirations, particularly for RITUXAN royalties outside the U.S. starting in late 2009.
06—Continue